ArticleThe Journal of clinical investigation2008
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.
Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 273 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
273 citing papers in PubMed, 2 syntheses or guidelines pooled it, 504 citations in OpenAlex.
- Knowledge mapping of DNGR-1 on dendritic cells in immunotherapy: a review and bibliometric study.Frontiers in immunology · 2026Pooled it
- Cell and tissue engineering in lymph nodes for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- A multi-omics-based investigation of the prognostic and immunological impact of necroptosis-related mRNA in patients with cervical squamous carcinoma and adenocarcinoma.Scientific reports · 2022Trial
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.Nature medicine · 2019Trial
- Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.Vaccines · 2026Review
- Article
- Control of poorly immunogenic tumors with systemic STING agonist-loaded liposomes targeting cross-presenting dendritic cells.Clinical & translational immunology · 2026Article
- Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity.Nature immunology · 2026Article
- Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform.Drug delivery · 2025Article
- Review
- Boosting Dendritic Cell Function in Cancer.Cancer medicine · 2025Review
- DNGR-1 regulates proliferation and migration of bone marrow dendritic cell progenitors.The Journal of experimental medicine · 2025Article
- cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy.Circulation research · 2025Article
- Cross-priming in cancer immunology and immunotherapy.Nature reviews. Cancer · 2025Review
- Article
- MAIT cells protect against sterile lung injury.Cell reports · 2025Article
- Article
- Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.NPJ vaccines · 2025Review
- The Dectin-1 and Dectin-2 clusters: C-type lectin receptors with fundamental roles in immunity.EMBO reports · 2024Review
- Development of a Versatile Cancer Vaccine Format Targeting Antigen-Presenting Cells Using Proximity-Based Sortase A-Mediated Ligation of T-Cell Epitopes.Bioconjugate chemistry · 2024Article
213 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
The mouse CD8alpha+ DC subset excels at cross-presentation of antigen, which can elicit robust CTL responses. A receptor allowing specific antigen targeting to this subset and its equivalent in humans would therefore be useful for the induction of antitumor CTLs. Here, we have characterized a C-type lectin of the NK cell receptor group that we named DC, NK lectin group receptor-1 (DNGR-1). DNGR-1 was found to be expressed in mice at high levels by CD8+ DCs and at low levels by plasmacytoid DCs but not by other hematopoietic cells. Human DNGR-1 was also restricted in expression to a small subset of blood DCs that bear similarities to mouse CD8alpha+ DCs. The selective expression pattern and observed endocytic activity of DNGR-1 suggested that it could be used for antigen targeting to DCs. Consistent with this notion, antigen epitopes covalently coupled to an antibody specific for mouse DNGR-1 were selectively cross-presented by CD8alpha+ DCs in vivo and, when given with adjuvants, induced potent CTL responses. When the antigens corresponded to tumor-expressed peptides, treatment with the antibody conjugate and adjuvant could prevent development or mediate eradication of B16 melanoma lung pseudometastases. We conclude that DNGR-1 is a novel, highly specific marker of mouse and human DC subsets that can be exploited for CTL cross-priming and tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.